Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First US product approval for Taiho Oncology

This article was originally published in Scrip

Executive Summary

The US FDA has approved Taiho Pharmaceuticals Co. Ltd.'s Lonsurf (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of metastatic colorectal cancer (mCRC). It is the first approval for Taiho's US oncology division. Launch is expected within the next two weeks but Lonsurf's price has yet to be disclosed.

You may also be interested in...



Merck Joins KRAS Stampede In Deal With Otsuka Affiliates

Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.

VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others

Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC029848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel